AstraZeneca has made management changes that include an expanded membership of its senior executive team.


AstraZeneca, pharmaceutical manufacturer, senior executive team, management changes, R&D, biologics, Pascal Soriot, Martin Mackay, Tony Zook






































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

AstraZeneca announces senior exec changes

January 16th, 2013

LONDON – AstraZeneca has made management changes that include an expanded membership of its senior executive team.

The pharmaceutical manufacturer said Tuesday that the changes include the creation of three senior research-and-development roles responsible for discovery and early-stage development in small molecules, discovery and early-stage development in biologics, and late-stage development.

AstraZeneca said it also has created three roles representing its North America, Europe and iternational commercial regions as well as a role responsible for global portfolio and product strategy, bridging the R&D and sales organizations.

With the moves, two senior roles — president of R&D, held by Martin Mackay, and executive vice president for global commercial, held by Tony Zook — have been eliminated. Mackay and Zook will leave the company at the end of January, according to AstraZeneca.

The full senior executive team includes Pascal Soriot, chief executive officer and executive director; Simon Lowth, chief financial officer and executive director; Mene Pangalos,  executive vice president, innovative medicines; Bahija Jallal, executive vice president, MedImmune; Briggs Morrison, executive vice president, global medicines development; Paul Hudson, executive vice president, North America; Ruud Dobber, executive vice president, Europe; Mark Mallon, executive vice president, international; David Smith, executive vice president, operations and IS; Lynn Tetrault, executive vice president, human resources and Corporate Affairs; Katarina Ageborg, chief compliance officer; and Jeff Pott, general counsel.

AstraZeneca added that the appointment of the executive vice president for global portfolio and product strategy will be made at a later date.

"This new senior executive team structure, that draws heavily from the leadership talent within the company, enables us to bring an even sharper management focus to key pipeline assets, key brands and key markets and helps us further accelerate decision-making," CEO Pascal Soriot stated.

Advertisement